Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab - ODYSSEY OUTCOMES


CONTRIBUTION TO LITERATURE: The ODYSSEY OUTCOMES trial showed that use of alirocumab, taken every other week, significantly reduces ischemic events, including all-cause mortality and MI, compared with placebo among patients with an ACS event within the preceding 1-12 months.

DESCRIPTION: The goal of the trial was to compare the safety and efficacy of alirocumab compared with placebo among patients with recent acute coronary syndrome (ACS) already on intensive or maximum-tolerated statin therapy.

STUDY DESIGN: Patients who were 1-12 months out from an ACS event were randomized, after a run-in phase of 2-16 weeks on high-intensity statin therapy, to alirocumab q2 weeks (n = 9,462 subcutaneously or placebo (n = 9,462). Drug was titrated between 75 and 150 mg to keep the low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dl, but above 15 mg/dl.

Read More